This year, the Food and Drug Administration announced it was taking steps to help gene therapies gain accelerated approval. Throughout 2022, the FDA approved three new gene therapy treatments for adult patients with various health issues including bladder cancer, Hemophilia B and more.

In April, scientists at Trinity College Dublin announced a significant development towards a new therapeutic treatment of glaucoma.

As scientists continue to make strides in gene therapy to provide new treatments and companies evaluate these health care options, consumers are fearing exorbitantly high costs, and insurers are left with questions on how this impacts plans and policies.